The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?

Area of Science:

• Cardiology and Molecular Biology
• Biomarkers in Cardiovascular Disease

Background:

• Heart failure (HF) is a growing clinical syndrome with high morbidity and mortality.
• Galectin-3 (Gal-3) is implicated in HF pathophysiology, particularly cardiac fibrosis, inflammation, and ventricular remodeling.
• Cardiac fibrosis is a key feature of HF and atrial fibrillation.

Purpose of the Study:

• To review the role of Gal-3 in the pathogenesis of HF.
• To explore the clinical diagnostic and prognostic significance of Gal-3 in HF.
• To discuss Gal-3's potential as a therapeutic target for HF.

Main Methods:

• Review of existing literature on Gal-3 structure and function in HF.
• Analysis of studies correlating Gal-3 serum concentration with echocardiographic and CMR biomarkers in HF.
• Discussion of Gal-3's utility in various HF settings (acute/chronic, preserved/reduced ejection fraction).

Main Results:

• Gal-3 plays a crucial role in molecular mechanisms driving HF development.
• Numerous studies link elevated Gal-3 serum levels to HF biomarkers.
• Gal-3 shows potential for diagnosis, prognosis, and risk stratification in HF.

Conclusions:

• Gal-3 is a significant factor in HF pathogenesis, particularly fibrosis and remodeling.
• Gal-3 serum concentration is associated with HF severity and biomarkers.
• Gal-3 represents a promising therapeutic target for managing heart failure.